North Carolina Biotechnology Center Announces Company Sponsors for New Industrial Fellowship
The North Carolina Biotechnology Center has announced the five sponsoring companies chosen for the first year of its Industrial Fellowship Program.
The North Carolina Biotechnology Center has announced the five sponsoring companies chosen for the first year of its Industrial Fellowship Program. The companies chosen are:
- Affinergy Inc. in Durham, which is focused on site-specific biological delivery systems (www.affinergy.com);
- Aldagen Inc. in Durham, which develops proprietary cell therapies (www.aldagen.com);
- BASF’s plant science group in Research Triangle Park; BASF is an international agribusiness company (www.basf.com/plantscience);
- Winston-Salem-based Targacept, a clinical-stage biopharmaceutical company (www.targacept.com);
- Tengion in Winston-Salem, which develops neo-organs and tissues (www.tengion.com).
A total of 18 companies applied for the program, which pays two years of salary and benefits for a postdoctoral researcher with academic-only laboratory experience to work in an industrial setting. Additionally, the industrial fellows will have access to programs in business, intellectual property, regulatory affairs, and other areas to complement their training. Fellows selected and hired by sponsoring companies will begin on October 15. The industrial fellowship program is designed to fill a gap for scientists in need of industry experience as well as for companies in need of scientific expertise. Few companies offer transitional opportunities, and PhD scientists coming out of academia are often dismissed as being overqualified for technical jobs but not qualified enough for senior positions.
For more information on the program please visit www.ncbiotech.org/fellowship.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
